Literature DB >> 2137827

Mutants in signal transduction through the T-cell antigen receptor.

J G Wong1, A Rao.   

Abstract

Mutants of an untransformed helper T-cell clone have been derived by chemical mutagenesis followed by selection for cells incapable of proliferating in response to antigen or anti-CD3. The selection was designed to enrich cells bearing mutations distal to the T-cell antigen receptor. The mutants express normal levels of functional T-cell receptors but are uncoupled from cellular responses, including gene induction, lymphokine secretion, proliferation, and phosphatidylinositol turnover. Responses to phorbol ester plus calcium ionophore and to interleukin-2 are unimpaired. Responses to antigen were restored by fusion with a T-cell receptor-negative thymoma, making the mutants valuable for investigating the mechanisms that couple T-cell receptor stimulation to the induction of second messengers and subsequent physiologic responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137827

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Cyclosporin A sensitivity of the NF-kappa B site of the IL2R alpha promoter in untransformed murine T cells.

Authors:  P G McCaffrey; P K Kim; V E Valge-Archer; R Sen; A Rao
Journal:  Nucleic Acids Res       Date:  1994-06-11       Impact factor: 16.971

2.  Normal peripheral T-cell function in c-Fos-deficient mice.

Authors:  J Jain; E A Nalefski; P G McCaffrey; R S Johnson; B M Spiegelman; V Papaioannou; A Rao
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

3.  Functional analysis of the antigen binding site on the T cell receptor alpha chain.

Authors:  E A Nalefski; S Kasibhatla; A Rao
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

4.  The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.

Authors:  J Jain; V E Valge-Archer; A J Sinskey; A Rao
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.